Randomized trial experience of the Intergroupe Francophone du Myélome

Seminars in Hematology

Volumn 38, Issue 3, 2001, Pages 226-230

  Attal, Michel ^a,b   Harousseau, Jean Luc ^a,b  

^a CHU PURPAN   (France)

^b HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DOXORUBICIN; MELPHALAN; VINCRISTINE;

ADULT; AGED; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; EXPERIENCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SURVIVAL TIME; TANDEM REPEAT; WHOLE BODY RADIATION;

EID: 0034884404     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0037-1963(01)90014-9     Document Type: Article

References (12)

1. Autologous transplantation in multiple myeloma
2. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma
3. Bone marrow transplantation in multiple myeloma
4. Autologous stem cell transplantation in multiple myeloma: Results of the European Group for Bone Marrow Transplantation
5. Double high-dose chemoradiotherapy with autologous stem cell transplantation can induce molecular remissions in multiple myeloma
6. High dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma
7. 2-microglobulin produce a very powerful myeloma staging system for patients receiving high-dose therapy
8. Comparison of autologous bone marrow transplantation and peripheral blood stem cell transplantation after first remission induction treatment in multiple myeloma
9. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: A report of the French Registry on Autologous Transplantation in Multiple Myeloma
10. 2 as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed myeloma
11. Autotransplant in multiple myeloma: What have we learned?
12. High-dose therapy for refractory multiple myeloma: Improved prognosis with better supportive care and double transplants